1 / 15

e-Therapeutics plc

e-Therapeutics plc. The Network Pharmacology Company. Preliminary year-end results 2012 May 22 2012.

mufutau-bell
Download Presentation

e-Therapeutics plc

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. e-Therapeutics plc The Network Pharmacology Company Preliminary year-end results 2012 May 22 2012

  2. These presentation materials are directed only at persons who fall within the exemptions contained in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2006 including investment professionals, high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts) and persons who are otherwise permitted by law to receive them and has not been approved by an authorised person as would otherwise be required by section 21 of the Financial Services and Markets Act 2000. These presentation materials are directed only at persons having professional experience in matters relating to investments and any investment or investment activity to which these presentation materials relate is available only to such persons. Persons of any other description, including those who do not have professional experience in matters relating to investments, should not rely on these presentation materials or act upon their content. Any investment to which this document relates is available to (and any investment activity to which it relates will be engaged with) only those persons described above. Persons who do not fall within these categories of investor should not take any action upon this document, but should return it immediately to Panmure Gordon (UK) Limited (“Panmure Gordon”). Postage and other reasonable delivery costs will be refunded. It is a condition of your receiving this document that you fall within, and you warrant to e-Therapeutics plc (the “Company”) and Panmure that you fall within, the categories of person described above. The presentation materials do not constitute or form any part of any offer or invitation to sell or issue or purchase or subscribe for any shares in the Company nor shall they or any part of them, or the fact of their distribution, form the basis of, or be relied on in connection with, any contract with the Company relating to any securities. Any decision regarding any proposed subscription for shares in the Company must be made solely on the basis of public information on the Company. The presentation materials are not intended to be distributed or passed on, directly or indirectly, or to any other class of persons. They are being supplied to you solely for your information and may not be reproduced, forwarded to any other person or published, in whole or in part, for any other purpose. No reliance may be placed for any purpose whatsoever on the information contained in this document or on its completeness. Any reliance on this communication could potentially expose you to a significant risk of losing all of the property invested by you or the incurring by you of additional liability. No representation or warranty, express or implied, is given by the Company, its directors or employees, or Panmure or their professional advisers as to the accuracy, fairness, sufficiency or completeness of the information, opinions or beliefs contained in this document. Save in the case of fraud, no liability is accepted for any loss, cost or damage suffered or incurred as a result of the reliance on such information, opinions or beliefs. Certain statements and graphs throughout the presentation are “forward-looking statements” and represent the Company’s internal projects, expectations or beliefs concerning, among other things, future operating results and various components thereof or the Company’s future economic performance. The projections, estimates and beliefs contained in such forward-looking statements necessarily involve known and unknown risks and uncertainties which may cause the Company’s actual performance and financial results in future periods to differ materially from any estimates or projections. If you are in any doubt about the investment to which these presentation materials relate, you should consult a person authorised by the Financial Services Authority who specialises in advising on securities of the kind described in this document. Safe harbour statement / disclaimer 2

  3. e-Therapeutics’ business model • Discovery • Discovery scientists working with Network Pharmacology platform • Generate candidates for development • Development • Core internal team led by Steve Self + specialist CROs, CMOs • Advance drugs through phase II trials Potential discovery collaborations Product licensing deals 3

  4. Drug discovery Oxford Network Pharmacology Centre established New wave of discovery started Focus on cancer and neurodegenerative diseases Expect at least one new drug for development by end 2013 Further innovations in platform approach – new IP Highlights of 2011/12 (1) 4

  5. Drug development MHRA approved plans for ETS2101 ‘all-comers’ ph I FDA approved plans for ph I study in brain cancer Both ETS201 trials expected to start enrolment soon ETX1153c; plans changed; new preclinical work On track to start phIIb trial of ETS6103 (depression) in Q3 On track to start ph I trial of ETX1153a (MRSA) in Q4 Highlights of 2011/12 (2) 5

  6. Finance Cash and deposits of £13.9m at Jan 31 ‘12 (2011: £0.9m) Balance sheet transformed by Feb ‘11 raise of £16.7m Net loss of £3.2m (2011: loss of £2.3m) Increasing investment in R&D Organisation Daniel Elger and Rajesh Chopra appointed to Board New scientific talent recruited Highlights of 2011/12 (3) 6

  7. ETX programme focused on evasion of apoptosis Began with genes implicated in evasion of apoptosis Built protein networks including products of these genes proteins regulating their expression  103 interactome local area networks (LANs) Used impact analysis to identify best sets of target proteins per LAN and then overall desired protein signature ETS2101 – anticancer candidate1. Targeting strategy developed using network pharmacology 7

  8. Matched desired signature with footprints of known molecules using chemoproteomic resources One of 16 was ETS2101 = dexanabinol, a synthetic cannabinoid that had failed phase III in trauma patients Well tolerated Distinctive footprint NMDA receptor Binding affinity COX2 Gene expression/ regulation TNFa Post-translation / secretion NF-kBPhosphorylation CDP-diacylglycerol-glycerol- 3-phosphate 3 phosphatidyltransferase Network-mediated Farnesyltranstransferase Network-mediated Histoneacetyltransferase Network-mediated CDK2 Network-mediated CDK5 Network-mediated ETS2101 – anticancer candidate 2. Drugs to deliver strategy identified 8

  9. NP platform predicted ETS2101 would stop cancer cells evading apoptosis Preclinical testing showed broad and potent anti-cancer activity Wide variety of cancer cell lines Particularly interesting results in brain cancer glioma ETS2101 – anticancer candidate 3. Empirical testing supported network pharmacology predictions Killing of four brain cancer cell lines by ETS2101 9

  10. Two parallel phase I trials to be conducted #1 – patients with a variety of solid tumours - UK #2 – patients with brain cancers (primary and metastatic) - US Both trials will explore dosing, safety and activity Trials approved by regulators, starting shortly Initial data expected by end of 2012 Final data from both studies expected 2013 ETS2101 – anticancer candidate4. Clinical development about to begin 10

  11. Product with promising preclinical data in treatment of Clostridium difficile, a cause of life-threatening infections High potency based on synergistic combination of nisin and miconazole Activity extends to drug-resistant strains such as NAP-1 Issues in formulating drug & potential for better product so not progressing immediately with clinical development New preclinical work to build on positive findings with ETX1153c and recent data on related approaches ETX1153c – anti-infective vs C. difficile 11

  12. ETS6103 - depression Building on encouraging phase IIa trial data Phase IIb trial to start Q3 2012, report H2 2013 ETX1153a - MRSA Topical approach to MRSA Phase I study to start Q4 2012, report 2013 Two further clinical entrants in 2012 12

  13. Solid progress • 2011 • Business funded until 2014 • Restart of discovery: new hires • Preparation for trials • 2012 • Discovery fully active • Trial starts for 3 drugs • First trial data • Ramp-up of BD activity • Increasing interest in NP approach 13

  14. R&D investment and returns For two financial years to Jan 2014 £13.9m Jan ’12 • Development • ~2/3 of R&D investment • Three drugs into clinic in ‘12 • Significant data in 2012/13 (1 phase II & 2 phase I results by end of 2013) • Discovery • ~1/3 of R&D investment • New wave underway • One + new drug into development by end 2013 Product licensing deals Potential discovery collaborations 14

  15. Newsflow 2012-2013 15

More Related